Cytotoxic chemotherapy and epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies remain the standard treatment option for a recurring disease that is no longer responsive to local therapy or metastatic HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.